Last reviewed · How we verify
NCT04918212
Safety and Efficacy Study of Fabulous Stent Graft System for Stanford B Aortic Dissection
NA trial testing Fabulous Stent Graft System in Aortic Dissection Type B in 148 participants. Completed in 13 October 2020.
13 October 2020
Quick facts
| Lead sponsor | Hangzhou Endonom Medtech Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 148 |
| Start date | 25 November 2017 |
| Primary completion | 13 October 2020 |
| Estimated completion | 13 October 2020 |
| Sites | 24 locations across China |
Drugs / interventions tested
- Fabulous Stent Graft System
Conditions studied
- Aortic Dissection Type B — all drugs for Aortic Dissection Type B →
Sponsor
Hangzhou Endonom Medtech Co., Ltd.
Who can join
18 and older, any sex, with Aortic Dissection Type B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, multi-center, objective performance criteria clinical trial to evaluate the safety and efficacy of Fabulous Stent Graft System manufactured by Hangzhou Endonom Medtech Co., Ltd. for Stanford B Aortic Dissection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04918212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Dissection Type B
Currently open trials in the same condition.
- NCT07143071 — EndoVascular Aortic Dissection Early vs Delayed · active not recruiting
Other Hangzhou Endonom Medtech Co., Ltd. trials
Trials by the same sponsor.
- NCT07170332 — ZIPPER™ Stent-Graft Trial for Aortic Arch Dissection · NA · not yet recruiting
- NCT06385379 — Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study) · NA · recruiting
- NCT06062524 — Guo's False Lumen Embolization : The First in Man Study of WeFlow-EndoSeal Aorta Vascular Plug System · NA · recruiting
- NCT05872282 — Percutaneous Endovascular Arch Repair Trial (PEART) Study · NA · unknown
- NCT05754541 — Guo's Endovascular Aortic Arch Replacement of Aortic Dissection by WeFlow-Tribranch Endoprothesis: a Multicenter Pilot S · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04918212 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hangzhou Endonom Medtech Co., Ltd.
- Last refreshed: 8 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04918212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing